Multiplexed tandem polymerase chain reaction identifies strong expression of oestrogen receptor and Her-2 from single, formalin-fixed, paraffin-embedded breast cancer sections

Pathology

Volumn 42, Issue 2, 2010, Pages 165-172

  Thompson, Erik W ^a   Warton, Kristina ^a   Blick, Tony ^a   Wafai, Razan ^a   Hill, Prue ^a   Stanley, Keith ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Breast tumour; Her 2; MT PCR; Oestrogen receptor; Treatment directed diagnosis

Indexed keywords

EID: 75649124161     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.3109/00313020903494102     Document Type: Article

References (28)

1. Pakkiri P, Lakhani SR, Smart CE. Current and future approach to the pathologist's assessment for targeted therapy in breast cancer. Pathology 2009; 41: 89-99.
2. Sotiriou C, Piccart MJ. Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? Nat Rev Cancer 2007; 7: 545-553
3. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752
4. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-10874
5. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100: 8418-8423
6. Cronin M, Pho M, Dutta D, et al. Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am J Pathol 2004; 164: 35-42.
7. Stanley KK, Szewczuk E. Multiplexed tandem PCR: gene profiling from small amounts of RNA using SYBR Green detection. Nucleic Acids Res 2005; 33: e180.
8. Kouros-Mehr H, Bechis SK, Slorach EM, et al. GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. Cancer Cell 2008; 13: 141-152
9. Kouros-Mehr H, Kim JW, Bechis SK, Werb Z. GATA-3 and the regulation of the mammary luminal cell fate. Curr Opin Cell Biol 2008; 20: 164-170
10. Parikh P, Palazzo JP, Rose LJ, Daskalakis C, Weigel RJ. GATA-3 expression as a predictor of hormone response in breast cancer. J Am Coll Surg 2005; 200: 705-710
11. Fang SH, Chen Y, Weigel RJ. GATA-3 as a marker of hormone response in breast cancer. J Surg Res 2008; Aug 26: (Epub ahead of print).
12. Stein D, Wu J, Fuqua SA, et al. The SH2 domain protein GRB-7 is coamplified, overexpressed and in a tight complex with HER2 in breast cancer. Embo J 1994; 13: 1331-1340
13. Rody A, Karn T, Ruckhaberle E, et al. Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer. Breast Cancer Res Treat 2009; 113: 457-466
14. Stanley K, Szewczuk E. Multiplexed tandem PCR: Gene profiling from small amounts of RNA using SYBR green detection. Nucleic Acids Res 2005; 33: e180.
15. Shousha D, Peston D. Immunohistochemical demonstration of oestrogen andd progesterone receptors in paraffin sections of breast cancer. Curr Diagn Pathol 1997; 4: 176-180
16. Sharp JA, Waltham M, Williams ED, Henderson MA, Thompson EW. Transfection ofMDA-MB-231 human breast carcinoma cells with bone sialoprotein (BSP) stimulates migration and invasion in vitro and growth of primary and secondary tumors in nude mice. Clin Exp Metastasis 2004; 21: 19-29.
17. De Ferrari L, Aitken S. Mining housekeeping genes with a Naive Bayes classifier. BMC Genomics 2006; 7: 277.
18. Sotiriou C, Neo SY, McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a populationbased study. Proc Natl Acad Sci USA 2003; 100: 10393-10398
19. Yu D, Hung MC. Overexpression of ErbB2 in cancer and ErbB2- targeting strategies. Oncogene 2000; 19: 6115-6121
20. Kim C, Taniyama Y, Paik S. Gene expression-based prognostic and predictive markers for breast cancer: a primer for practicing pathologists. Arch Pathol Lab Med 2009; 133: 855-859
21. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptorpositive breast cancer. J Clin Oncol 2006; 24: 3726-3734
22. Sparano JA, Paik S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 2008; 26: 721-728
23. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-536
24. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999-2009.
25. Sorlie T. Molecular classification of breast tumors: toward improved diagnostics and treatments. Methods Mol Biol 2006; 360: 91-114.
26. Liu R, Wang X, Chen GY, et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 2007; 356: 217-226
27. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303: 844-848
28. Shangary S, Wang S. Targeting the MDM2-p53 interaction for cancer therapy. Clin Cancer Res 2008; 14: 5318-5324